Published in Women's Health Weekly, October 31st, 2002
These articles are another important milestone for this promising new hormonal agent, and their publication follows the recent approval of Faslodex by the U.S. Food and Drug Administration (FDA) for the treatment of advanced breast cancer.
These publications mark an important step in defining the role of Faslodex. Importantly, the JCO chose to place the papers on early release...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.